Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jun;40(6):1346–1351. doi: 10.1128/aac.40.6.1346

Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.

C A Deminie 1, C M Bechtold 1, D Stock 1, M Alam 1, F Djang 1, A H Balch 1, T C Chou 1, M Prichard 1, R J Colonno 1, P F Lin 1
PMCID: PMC163329  PMID: 8725999

Abstract

Current treatments for human immunodeficiency virus (HIV) include both reverse transcriptase and protease inhibitors. Results from in vitro and clinical studies suggest that combination therapy can be more effective than single drugs in reducing viral burden. To evaluate compounds for combination therapy, stavudine (d4T), didanosine (ddI), or BMS-186,318, an HIV protease inhibitor, were combined with other clinically relevant compounds and tested in a T-cell line (CEM-SS) that was infected with HIV-RF or in peripheral blood mononuclear cells infected with a clinical HIV isolate. The combined drug effects were analyzed by the methods described by Chou and Talalay (Adv. Enzyme Regul. 22:27-55, 1984) as well as by Prichard et al. (Antimicrob. Agents Chemother. 37:540-545, 1993). The results showed that combining two nucleoside analogs (d4T-ddI, d4T-zidovudine [AZT], and d4T-zalcitabine [ddC]), two HIV protease inhibitors (BMS-186,318-saquinavir, BMS-186,318-SC-52151, and BMS-186,318-MK-639) or a reverse transcriptase and a protease inhibitor (BMS-186,318-d4T, BMS-186,318-ddI, BMS-186,318-AZT, d4T-saquinavir, d4T-MK-639, and ddI-MK-639) yielded additive to synergistic antiviral effects. In general, analysis of data by either method gave consistent results. In addition, combined antiviral treatments involving nucleoside analogs gave slightly different outcomes in the two cell types, presumably because of a difference in phosphorylation patterns. Importantly, no strong antagonism was observed with the drug combinations studied. These data should provide useful information for the design of clinical trials of combined chemotherapy.

Full Text

The Full Text of this article is available as a PDF (366.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bechtold C. M., Patick A. K., Alam M., Greytok J., Tino J. A., Chen P., Gordon E., Ahmad S., Barrish J. C., Zahler R. Antiviral properties of aminodiol inhibitors against human immunodeficiency virus and protease. Antimicrob Agents Chemother. 1995 Feb;39(2):374–379. doi: 10.1128/aac.39.2.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bianchi V., Borella S., Calderazzo F., Ferraro P., Chieco Bianchi L., Reichard P. Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8403–8407. doi: 10.1073/pnas.91.18.8403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Caliendo A. M., Hirsch M. S. Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis. 1994 Apr;18(4):516–524. doi: 10.1093/clinids/18.4.516. [DOI] [PubMed] [Google Scholar]
  4. Chong K. T., Pagano P. J., Hinshaw R. R. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3'-azido-3'-deoxythymidine or 2',3'-dideoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 1994 Feb;38(2):288–293. doi: 10.1128/aac.38.2.288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  6. Cooley T. P., Kunches L. M., Saunders C. A., Ritter J. K., Perkins C. J., McLaren C., McCaffrey R. P., Liebman H. A. Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial. N Engl J Med. 1990 May 10;322(19):1340–1345. doi: 10.1056/NEJM199005103221902. [DOI] [PubMed] [Google Scholar]
  7. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem Pharmacol. 1994 Jan 20;47(2):155–169. doi: 10.1016/0006-2952(94)90001-9. [DOI] [PubMed] [Google Scholar]
  8. Eron J. J., Jr, Johnson V. A., Merrill D. P., Chou T. C., Hirsch M. S. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother. 1992 Jul;36(7):1559–1562. doi: 10.1128/aac.36.7.1559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  10. Fischl M. A., Stanley K., Collier A. C., Arduino J. M., Stein D. S., Feinberg J. E., Allan J. D., Goldsmith J. C., Powderly W. G. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med. 1995 Jan 1;122(1):24–32. doi: 10.7326/0003-4819-122-1-199501010-00004. [DOI] [PubMed] [Google Scholar]
  11. Fitzgibbon J. E., Howell R. M., Haberzettl C. A., Sperber S. J., Gocke D. J., Dubin D. T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother. 1992 Jan;36(1):153–157. doi: 10.1128/aac.36.1.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Gao W. Y., Johns D. G., Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides. Mol Pharmacol. 1994 Oct;46(4):767–772. [PubMed] [Google Scholar]
  13. Getman D. P., DeCrescenzo G. A., Heintz R. M., Reed K. L., Talley J. J., Bryant M. L., Clare M., Houseman K. A., Marr J. J., Mueller R. A. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. J Med Chem. 1993 Jan 22;36(2):288–291. doi: 10.1021/jm00054a014. [DOI] [PubMed] [Google Scholar]
  14. Hammer S. M., Kessler H. A., Saag M. S. Issues in combination antiretroviral therapy: a review. J Acquir Immune Defic Syndr. 1994;7 (Suppl 2):S24–S37. [PubMed] [Google Scholar]
  15. Hartshorn K. L., Vogt M. W., Chou T. C., Blumberg R. S., Byington R., Schooley R. T., Hirsch M. S. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. Antimicrob Agents Chemother. 1987 Feb;31(2):168–172. doi: 10.1128/aac.31.2.168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Johnson V. A., Barlow M. A., Merrill D. P., Chou T. C., Hirsch M. S. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. J Infect Dis. 1990 Jun;161(6):1059–1067. doi: 10.1093/infdis/161.6.1059. [DOI] [PubMed] [Google Scholar]
  17. Johnson V. A., Merrill D. P., Chou T. C., Hirsch M. S. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. J Infect Dis. 1992 Nov;166(5):1143–1146. doi: 10.1093/infdis/166.5.1143. [DOI] [PubMed] [Google Scholar]
  18. Johnson V. A., Merrill D. P., Videler J. A., Chou T. C., Byington R. E., Eron J. J., D'Aquila R. T., Hirsch M. S. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J Infect Dis. 1991 Oct;164(4):646–655. doi: 10.1093/infdis/164.4.646. [DOI] [PubMed] [Google Scholar]
  19. Kageyama S., Weinstein J. N., Shirasaka T., Kempf D. J., Norbeck D. W., Plattner J. J., Erickson J., Mitsuya H. In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother. 1992 May;36(5):926–933. doi: 10.1128/aac.36.5.926. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Karlsson A., Reichard P., Eckstein F. Hydroxyurea increases the phosphorylation of 3'-fluorothymidine and 3'-azidothymidine in CEM cells. Eur J Biochem. 1989 Dec 22;186(3):689–694. doi: 10.1111/j.1432-1033.1989.tb15261.x. [DOI] [PubMed] [Google Scholar]
  21. Kempf D. J., Codacovi L., Wang X. C., Kohlbrenner W. E., Wideburg N. E., Saldivar A., Vasavanonda S., Marsh K. C., Bryant P., Sham H. L. Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol. J Med Chem. 1993 Feb 5;36(3):320–330. doi: 10.1021/jm00055a003. [DOI] [PubMed] [Google Scholar]
  22. Lambert D. M., Bartus H., Fernandez A. V., Bratby-Anders C., Leary J. J., Dreyer G. B., Metcalf B. W., Petteway S. R., Jr Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Antiviral Res. 1993 Aug;21(4):327–342. doi: 10.1016/0166-3542(93)90011-7. [DOI] [PubMed] [Google Scholar]
  23. Lambert J. S., Seidlin M., Reichman R. C., Plank C. S., Laverty M., Morse G. D., Knupp C., McLaren C., Pettinelli C., Valentine F. T. 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med. 1990 May 10;322(19):1333–1340. doi: 10.1056/NEJM199005103221901. [DOI] [PubMed] [Google Scholar]
  24. Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989 Mar 31;243(4899):1731–1734. doi: 10.1126/science.2467383. [DOI] [PubMed] [Google Scholar]
  25. Larder B. A., Kellam P., Kemp S. D. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature. 1993 Sep 30;365(6445):451–453. doi: 10.1038/365451a0. [DOI] [PubMed] [Google Scholar]
  26. Lin P. F., Samanta H., Rose R. E., Patick A. K., Trimble J., Bechtold C. M., Revie D. R., Khan N. C., Federici M. E., Li H. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994 Nov;170(5):1157–1164. doi: 10.1093/infdis/170.5.1157. [DOI] [PubMed] [Google Scholar]
  27. Malley S. D., Grange J. M., Hamedi-Sangsari F., Vila J. R. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds. Lancet. 1994 May 21;343(8908):1292–1292. doi: 10.1016/s0140-6736(94)92182-2. [DOI] [PubMed] [Google Scholar]
  28. Merigan T. C., Skowron G., Bozzette S. A., Richman D., Uttamchandani R., Fischl M., Schooley R., Hirsch M., Soo W., Pettinelli C. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus (HIV) infections. A phase I and II study. Ann Intern Med. 1989 Feb 1;110(3):189–194. doi: 10.7326/0003-4819-110-3-189. [DOI] [PubMed] [Google Scholar]
  29. Meyerhans A., Vartanian J. P., Hultgren C., Plikat U., Karlsson A., Wang L., Eriksson S., Wain-Hobson S. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol. 1994 Jan;68(1):535–540. doi: 10.1128/jvi.68.1.535-540.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Moulding T., Dutt A. K., Reichman L. B. Fixed-dose combinations of antituberculous medications to prevent drug resistance. Ann Intern Med. 1995 Jun 15;122(12):951–954. doi: 10.7326/0003-4819-122-12-199506150-00010. [DOI] [PubMed] [Google Scholar]
  31. Pagano P. J., Chong K. T. In vitro inhibition of human immunodeficiency virus type 1 by a combination of delavirdine (U-90152) with protease inhibitor U-75875 or interferon-alpha. J Infect Dis. 1995 Jan;171(1):61–67. doi: 10.1093/infdis/171.1.61. [DOI] [PubMed] [Google Scholar]
  32. Prichard M. N., Prichard L. E., Shipman C., Jr Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother. 1993 Mar;37(3):540–545. doi: 10.1128/aac.37.3.540. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Richman D. D. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother. 1993 Jun;37(6):1207–1213. doi: 10.1128/aac.37.6.1207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Roberts N. A., Martin J. A., Kinchington D., Broadhurst A. V., Craig J. C., Duncan I. B., Galpin S. A., Handa B. K., Kay J., Kröhn A. Rational design of peptide-based HIV proteinase inhibitors. Science. 1990 Apr 20;248(4953):358–361. doi: 10.1126/science.2183354. [DOI] [PubMed] [Google Scholar]
  35. Sørensen A. M., Nielsen C., Mathiesen L. R., Nielsen J. O., Hansen J. E. Evaluation of the combination effect of different antiviral compounds against HIV in vitro. Scand J Infect Dis. 1993;25(3):365–371. doi: 10.3109/00365549309008512. [DOI] [PubMed] [Google Scholar]
  36. Tino J. A., Clark J. M., Field A. K., Jacobs G. A., Lis K. A., Michalik T. L., McGeever-Rubin B., Slusarchyk W. A., Spergel S. H., Sundeen J. E. Synthesis and antiviral activity of novel isonucleoside analogs. J Med Chem. 1993 Apr 30;36(9):1221–1229. doi: 10.1021/jm00061a013. [DOI] [PubMed] [Google Scholar]
  37. Tisdale M., Kemp S. D., Parry N. R., Larder B. A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5653–5656. doi: 10.1073/pnas.90.12.5653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Vacca J. P., Dorsey B. D., Schleif W. A., Levin R. B., McDaniel S. L., Darke P. L., Zugay J., Quintero J. C., Blahy O. M., Roth E. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4096–4100. doi: 10.1073/pnas.91.9.4096. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Weislow O. S., Kiser R., Fine D. L., Bader J., Shoemaker R. H., Boyd M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst. 1989 Apr 19;81(8):577–586. doi: 10.1093/jnci/81.8.577. [DOI] [PubMed] [Google Scholar]
  40. Yerly S., Kaiser L., Baumberger C., Hirschel B., Perrin L. H. Early and prolonged decrease of viremia in HIV-1-infected patients treated with didanosine. J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):358–364. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES